// App-Quantinova.ai

666P : Accuracy and prognostic significance of oncologists’ estimates and scenarios for survival time in a randomised Phase 2 trial of regorafenib in advanced gastric cancer

Researchers

Presenter

  • A.Vasista

Principal Investigators

  • N.Pavlakis

  • K.Sjoquist

  • S.Snow

  • D.Jonker

  • Y.J.Chua

  • R.Epstein

  • A.Bonaventura

  • M.Khasraw

  • S.C.Varma

  • N.Singhal

  • D.T.Ransom

  • F.Aubin

  • R.Burkes

  • H.Lim

  • F.Lemay

  • S.Begbie

  • M.R.Stockler

  • B.Kiely

Medical Centers

  • Medical Oncology, NHMRC Clinical Trials Centre, Camperdown, Australia

  • Medical Oncology Department, Royal North Shore Hospital, St Leonards, Australia

  • Queen Elizabeth II Health Sciences Centre, Halifax, NS, Canada

  • Medicine, Ottawa Health Research Institute, Ottawa, ON, Canada

  • Medical Oncology Unit,The Canberra Hospital, Garran, Australia

  • Medical Oncology, St Vincent's Hospital, Melbourne, Australia

  • Medical Oncology, Newcastle Private Hospital, Newcastle, Australia

  • Medical Oncology, Geelong Hospital, Geelong, Australia

  • Rheumatology, Townsville Hospital, Douglas, Australia

  • Radiation Oncology, Royal Adelaide Hospital, Adelaide, Australia

  • Medical Oncology, St John of God, Subiaco, Australia

  • Medical Oncology, Hospital Notre Dame, Montreal, QC, Canada

  • Division of Gastroenterology, Mount Sinai Hospital, Toronto, Ontario, Canada

  • Medical Oncology, BCCA Vancouver Cancer Centre, Vancouver, BC, Canada

  • Paediatric Haematology/Oncology, Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, QC, Canada

  • Medical Oncology, North Coast Cancer Centre, Port Macquarie, Australia

Locations

  • Australia

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Regorafenib

Outcome

  • N/A


Study Design

  • Randomized

Phase

  • II

Study Id's

  • N/A

Sponsors

  • Merck Serono

Result

  • N/A